BPMC vs. FTSV, TPTX, DCPH, CLDX, SDGR, TEVA, ALNY, GMAB, RPRX, and BMRN
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Forty Seven (FTSV), Turning Point Therapeutics (TPTX), Deciphera Pharmaceuticals (DCPH), Celldex Therapeutics (CLDX), Schrödinger (SDGR), Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN).
Forty Seven (NASDAQ:FTSV) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
71.8% of Forty Seven shares are owned by institutional investors. 37.4% of Forty Seven shares are owned by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Blueprint Medicines received 379 more outperform votes than Forty Seven when rated by MarketBeat users. However, 68.12% of users gave Forty Seven an outperform vote while only 67.89% of users gave Blueprint Medicines an outperform vote.
Blueprint Medicines has a consensus target price of $108.00, suggesting a potential upside of 4.51%. Given Forty Seven's higher probable upside, analysts plainly believe Blueprint Medicines is more favorable than Forty Seven.
Forty Seven has higher earnings, but lower revenue than Blueprint Medicines. Forty Seven is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.
In the previous week, Blueprint Medicines had 13 more articles in the media than Forty Seven. MarketBeat recorded 13 mentions for Blueprint Medicines and 0 mentions for Forty Seven. Forty Seven's average media sentiment score of 0.44 beat Blueprint Medicines' score of 0.00 indicating that Blueprint Medicines is being referred to more favorably in the news media.
Forty Seven has a net margin of 0.00% compared to Forty Seven's net margin of -102.15%. Blueprint Medicines' return on equity of -50.38% beat Forty Seven's return on equity.
Forty Seven has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
Summary
Blueprint Medicines beats Forty Seven on 10 of the 18 factors compared between the two stocks.
Get Blueprint Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
